DK1401492T3 - LTB4 som vaccineadjuvans - Google Patents

LTB4 som vaccineadjuvans

Info

Publication number
DK1401492T3
DK1401492T3 DK02737698T DK02737698T DK1401492T3 DK 1401492 T3 DK1401492 T3 DK 1401492T3 DK 02737698 T DK02737698 T DK 02737698T DK 02737698 T DK02737698 T DK 02737698T DK 1401492 T3 DK1401492 T3 DK 1401492T3
Authority
DK
Denmark
Prior art keywords
ltb4
vaccine adjuvant
vaccine
enhancing
adjuvant
Prior art date
Application number
DK02737698T
Other languages
English (en)
Inventor
Pierre Borgeat
Louis Flamand
Jean Gosselin
Original Assignee
Ltb4 Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltb4 Sweden Ab filed Critical Ltb4 Sweden Ab
Application granted granted Critical
Publication of DK1401492T3 publication Critical patent/DK1401492T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
DK02737698T 2001-07-05 2002-06-26 LTB4 som vaccineadjuvans DK1401492T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30270501P 2001-07-05 2001-07-05
PCT/CA2002/000955 WO2003004054A1 (en) 2001-07-05 2002-06-26 Ltb4 as vaccine aduvant

Publications (1)

Publication Number Publication Date
DK1401492T3 true DK1401492T3 (da) 2009-09-14

Family

ID=23168877

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02737698T DK1401492T3 (da) 2001-07-05 2002-06-26 LTB4 som vaccineadjuvans

Country Status (8)

Country Link
US (1) US7914800B2 (da)
EP (1) EP1401492B1 (da)
AT (1) ATE431745T1 (da)
CA (1) CA2452008C (da)
DE (1) DE60232413D1 (da)
DK (1) DK1401492T3 (da)
ES (1) ES2329118T3 (da)
WO (1) WO2003004054A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473708B2 (en) 1996-02-15 2009-01-06 Jean Gosselin Agents with leukotriene B4-like antiviral (enveloped RNA) activities
WO2005102309A2 (en) * 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
CN101039698B (zh) 2004-09-20 2011-11-09 Ltb4瑞典公司 稳定的白三烯b4(ltb4)药剂的药学配方
US20130236496A1 (en) * 2010-06-29 2013-09-12 Universite De Laval Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-i-like receptor ligand, or a nod-like receptor ligand to enhance the innate immune response

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789441A (en) 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method

Also Published As

Publication number Publication date
EP1401492A1 (en) 2004-03-31
EP1401492B1 (en) 2009-05-20
CA2452008C (en) 2012-03-06
US20040208882A1 (en) 2004-10-21
ATE431745T1 (de) 2009-06-15
WO2003004054A1 (en) 2003-01-16
DE60232413D1 (en) 2009-07-02
US7914800B2 (en) 2011-03-29
ES2329118T3 (es) 2009-11-23
CA2452008A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
EP1504112A4 (en) DEVELOPMENT OF A VACCINE FOR THE PREVENTION OF INFECTIONS WITH THE FILOVIRUS IN PRIMATES
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
ATE426412T1 (de) Adjuvante influenza-vakzine
DE60210456D1 (de) Solubisierung von kapseln polysacchariden
CY2013036I1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
WO2006126981A3 (en) Compositions and methods for mucosal vaccination
GB2386072A (en) Novel vaccine
ATE521621T1 (de) Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
NO20023935D0 (no) Ny, ikke-antigen, mucosal adjuvantformulering som modulerer effektene av substanser, inkludert vaksineantigener, i kontakt medmucosale kroppsoverflater
DK1265633T3 (da) Vaccineadjuvans
WO2003066094A3 (en) Hepatitis b vaccines
GB2444676A (en) Adjuvanted vaccine
DK1395283T3 (da) Heterolog beskyttelse induceret ved immunisering med Invaplex-vaccine
DK1401492T3 (da) LTB4 som vaccineadjuvans
NO20024255L (no) HIV-immun adjuvansterapi
SG147465A1 (en) Vaccine
WO2006088997A3 (en) Adjuvant activities of b pentamers of lt-iia and lt-iib enterotoxin
WO2002032455A3 (en) Vaccine
HU0102823D0 (en) A broad spectrum infectious bursal disease virus vaccine
WO2004083390A3 (en) Virulent systemic feline calicivirus
AR026913A1 (es) Analogos de (1s-cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales